Research at EyeCare Partners

Advancing the Field of Eye Care, One Clinical Trial at a Time

EyeCare Partners is committed to innovation and elevating eye care for everyone. ECP is home to world-renowned centers of eye care excellence and leaders from every specialty and subspecialty. The eye doctors and research staff at ECP have been conducting clinical research for more than 35 years and have participated in over 500 research studies. Our goal is to pave the way for tomorrow’s eye care and bring it to our patients today.

The EyeCare Partners practices participate in numerous studies across all subspecialties for adult, these include dry eye, glaucoma, cataracts, macular degeneration, diabetes and more. Explore our current clinical research studies with open enrollment and complete the form to learn more about taking part.

Current Clinical Research Studies
Clinical Study Sponsors

Doctor posing for a photo in the exam room

How Does Clinical Research Help Our Patients?

Thousands of patients with eye problems come to an EyeCare Partners practice each week to find leading-edge solutions to their eye care needs. Our participation in clinical research allows us to offer patients the most advanced treatment options possible.

Staying on the Leading Edge of Eye Care Research

Our ongoing commitment to physician-controlled eye care research enables us to:

Provide patients with new and improved treatment options
Be at the forefront of vision care advances
Create an environment for lifelong learning and advancement
Advance the future of eye health and vision

Clinical Study Sponsors

EyeCare Partners plays an active role in clinical research to advance the future of eye care. Our experienced eye doctors and specialized research teams partner with emerging and established pharmaceutical and biotechnology companies to explore the next generation of ocular treatments. EyeCare Partners has 20+ practices and over 100 Investigators that participate in more than 200 clinical trials and we look forward to continuing our commitment to state-of-the-art clinical research.

What Type of Clinical Research Happens at EyeCare Partners?

Our doctors are always seeking solutions for eye conditions and vision issues. The clinical trials at EyeCare Partners spans Phases 1-4 and a range of specialties. Examples of research topics include:

New and Innovative Ocular Medications

Dry Eye Medications and Treatments
Ocular Surface Disease
Glaucoma Medications
Wet and Dry Macular Degeneration
Diabetic Retinopathy
Diabetic Macular Edema
Inherited Retinal Disease
Uveitis

Novel Surgical Procedures, Devices, and Intraocular Implants

Intraocular Lenses for Cataract Surgery
Micro-Invasive Glaucoma Devices
Specialized Corneal Transplantation
Artificial Iris Devices
Diabetic Macular Edema
Wet Macular Degeneration

Meet Our Director of Clinical Research

Megan Kingdon, BSN, RN, COA, CCRC, Director of Clinical Research – EyeCare Partners

Megan Kingdon, Director of Clinical Research at EyeCare Partners, brings more than 20 years of expertise in ophthalmology and clinical research. She spent many of those years at the Cincinnati Eye Institute (CEI), starting as an ophthalmic technician and quickly moving into a clinical research coordinator role in Anterior Segment. She obtained her nursing degree and did a stent in obstetrics at UC Hospital before returning to CEI as the clinical research coordinator for the retina department, where she grew the department from three clinical trials to thirty active trials. In 2021, she became the Director of Clinical Research for CEI Vision Partners in the Retina Department and then following the acquisition by EyeCare Partners, she was made Director of Clinical Research for ECP, overseeing more than 20 practices across the country.

Megan has extensive medical and surgical clinical trial experience in a wide range of ophthalmological conditions, including cataracts and IOLs, artificial iris devices, age-related macular degeneration, diabetic retinopathy, geographic atrophy, macular edema, proliferative vitreo-retinopathy, retinal vein occlusion, vitreomacular traction and inherited retinal diseases. Megan holds a Bachelor’s of Science in biology and chemistry from Lawrence University and a Bachelor’s of Science in nursing from the University of Cincinnati. She is certified by the Association of Clinical Research Professionals.

Why Choose EyeCare Partners For Clinical Research?

Facilities

State-of-the-art imaging and diagnostic equipment
Dedicated, visual acuity testing rooms
Designated monitoring rooms with high speed internet and phone access

Staff

Experienced and award-winning eye doctors
Dedicated clinical research coordinators
Certified Ophthalmic Technicians and Photographers
Trained personnel for handling/preparing for transportation of dangerous goods

Process

Adherence to Good Clinical Practice guidelines
Customized standard operating procedures
Excellent subject retention
Direct oversight by the PI and Research Director

Current Clinical Research Studies

Kansas

Stiles EyeCare Excellence

Abbvie

A Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Ab Externo Implantation of Glaucoma Gel Stent

Alcon

THE HYDRUS® MICROSTENT NEW ENROLLMENT POST-APPROVAL STUDY: A PROSPECTIVE, NON-RANDOMIZED, MULTICENTER, SINGLE ARM, CLINICAL TRIAL (CONFIRM)

Glaukos

Multicenter, Randomized, Double-masked Trial to Evaluate the Safety and Efficacy of iDose® TR (travoprost intraocular implant) in Conjunction with the Placement of iStent infinite vs. iStent infinite Alone in Subjects with Open-angle Glaucoma or Ocular Hypertension

Sanoculis

An Observer-Masked, Single-Arm, Multicenter Study to Evaluate the Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma which is Not Controlled Despite Polypharmacy

Grene Vision Group

KOWA

A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Simultaneous Cataract

Genentech

A PHASE III, RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SATRALIZUMAB IN PARTICIPANTS WITH MODERATE-TO-SEVERE THYROID EYE DISEASE

Missouri

Ophthalmology Associates

Combangio/Kala

A Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Patients with Persistent Corneal Epithelial Defect (PCED)

New World Medical

A Prospective, Randomized, Multi-center Evaluation of the Safety and Effectiveness of the STREAMLINE®SURGICAL SYSTEM Compared to iStent Inject W® in Patients With Open-Angle Glaucoma

CXL Ophthalmics

A Multicenter, randomized, double masked sham controlled, parallel-group Phase 3 study to evaluate efficacy and safety of epithelium corneal crosslinking in patients aged 8-45 with keratoconus

B&L

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Ophthalmology Consultants

Glaukos

Oculis

A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 ophthalmic suspension in the Treatment of Inflammation and Pain Following Cataract Surgery.

BVI

Clinical Investigation of the Safety and Effectiveness of Monofocal PODEYE TORIC Intraocular Lens (IOL)

Texas

EyeCare Associates of East Texas

Not Enrolling Trials Currently

Florida

Eye Institute of West Florida

Nicox

Protocol NCX-470-03: A Phase 3, Randomized, Multi-Regional, Double-Masked, Parallel-Group Trial Evaluating the Safety and Efficacy of NCX 470 0.1% vs. Latanoprost 0.005% in Subjects with Open-Angle Glaucoma or Ocular Hypertension (Denali)

Spyglass

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy and Dose Response of the SpyGlass drug delivery platform

B&L

A Phase 4, Multicenter, Open-Label Study to Evaluate the Effect of Miebo™ on Preoperative Biometry/Keratometry and Postoperative Refractive Accuracy

Virginia

Retina Institute of Virginia

RegenxBio

A Randomized, partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants with nAMD.

EyeBio

A RANDOMIZED, DOUBLE-MASKED, MULTICENTER, 3-ARM PIVOTAL PHASE 2/3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVITREAL EYE103 COMPAREDWITH INTRAVITREAL RANIBIZUMAB (0.5MG) IN PARTICIPANTS WITH DIABETIC MACULAR EDEMA

Virginia Eye Consultants

CXL Ophthalmics

A Multicenter, randomized, double masked sham controlled, parallel-group Phase 3 study to evaluate efficacy and safety of epithelium corneal crosslinking in patients aged 8-45 with keratoconus

Combangio/Kala

A Study to Evaluate the Safety and Efficacy of KPI-012 Ophthalmic Solution in Patients with Persistent Corneal Epithelial Defect (PCED)

Claris

A Single-Arm Open-Label Study to Evaluate the Safety and Efficacy of CSB-001 Ophthalmic Solution 0.1% in Subjects with Corneal Scars

Kentucky

Retina Associates of Kentucky

Outlook Therapeutics

Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects with Neovascular Age-related Macular Degeneration; NORSE EIGHT

Bennett and Bloom

Jaeb Center for Health Research

Diabetes Endothelial Keratoplasty Study (DEKS): Impact of Diabetes on Corneal Transplant Success and Endothelial Cell Loss

Indiana

John Kenyon

RegenxBio

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD

Ohio

Cincinnati Eye Institute

RegenxBio

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD

Janssen

A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).

Glaukos

A PROSPECTIVE, MULTICENTER STUDY OF THE GLAUKOS® ISTENT INFINITE TRABECULAR MICRO-BYPASS SYSTEM MODEL IS3 IN SUBJECTS WITH MILD TO MODERATE PRIMARY OPEN-ANGLE GLAUCOMA

Genentech

A PHASE IIa MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO OPTIMIZE SUBRETINAL SURGICAL DELIVERY AND TO EVALUATE SAFETY AND ACTIVITY OF OPREGEN IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION

Beacon

A Phase 2/3, Randomized, Controlled, Masked, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Two Doses of AGTC-501, a Recombinant Adeno-associated Virus Vector Expressing RPGR (rAAV2tYF-GRK1-RPGR), Compared to an Untreated Control Group in Male

Ascidian

Open-Label, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Subretinal ACDN-01 in Participants with ABCA4-related Retinopathy

Genentech

A Phase IIIb/IV, Multicenter, Visual Assessor Masked Study of the Efficacy and Safety of the Port Delivery System with Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration Previously Treated with Intravitreal Agents Other than Ranibizumab.

CXL Ophthalmics

A Multicenter, randomized, double masked sham controlled, parallel-group Phase 3 study to evaluate efficacy and safety of epithelium corneal crosslinking in patients aged 8-45 with keratoconus

KOWA

Oculis

A Randomized, Double-masked, Vehicle-controlled Study Evaluating the Efficacy and Safety of OCS-01 ophthalmic suspension in the Treatment of Inflammation and Pain Following Cataract Surgery

CVP Physicians Dayton

Not Enrolling Trials Currently

Retina Vitreous Associates

Not Enrolling Trials Currently

Michigan

Associated Retinal Consultants

RegenxBio

A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical study to Evaluate the Efficacy & Safety of RGX-314 Gene Therapy in Participants with NAMD

A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in participants with nAMD

Adverum

Phase 2 Study to Assess Safety and Efficacy of ADVM-022 (AAV.7m8-aflibercept) in Anti-VEGF Treatment-Experienced Patients With Neovascular (Wet) Age-Related Macular Degeneration.

Rezolute

A Randomized, Double-Masked, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ402 in Participants with Diabetic Macular Edema (DME)

Lowry Medical Research Institute

MacTel NHOR A Natural History Observation and Registry Study of Macular Telangiectasia Type 2

EyePoint Pharmaceuticals

A Retrospective Registry Study to Collect Real-world Data on YUTIQ, a Fluocinolone Acetonide Intravitreal Implant, for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment CALM: Real-world data on YUTIQ (fluoCinolone Acetonide intravitreaL iMplant) 0.18 mg

Genentech

A Phase III, Multicenter, Randomized, Double-Masked, Sham-Controlled, Study To Investigate the Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of R)7200220 Administered Intravitreally In Patients With Uveitic Macular Edema.

A THREE-PART, PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF RO7250284 FOLLOWING INTRAVITREAL ADMINISTRATION OF MULTIPLE ASCENDING DOSES AND CONTINUOUS DELIVERY FROM THE PORT DELIVERY IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (BURGUNDY).

Janssen

A Phase 2b, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-Controlled Clinical Trial to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD).

Ocular Therapeutics

A Phase 3, Multicenter, Double-Masked, Randomized, ParallelGroup Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular AgeRelated Macular Degeneration

Vitreo-Retinal Associates

DRCR

Protocol AF: Randomized Trial Evaluating Fenofibrate for
Prevention of Diabetic Retinopathy Worsening

Oakland Ophthalmic Surgery

Samsara

A prospective, multicenter clinical study of the Implantable Miniature Telescope, Model SING in patients with central vision impairment associated with end-stage age-related macular degeneration (AMD)

Apthera

IC-8 APTHERA IOL NEW ENROLLMENT POST APPROVAL STUDY

Huron

Spyglass

A Prospective, Multicenter, Randomized, Masked, Controlled Study to Evaluate the Safety, Efficacy, and Dose-response of the Bimatoprost Implant System (39 mcg, 78 mcg) used in combination with the SpyGlass IOL Compared to Timolol Maleate Ophthalmic Solution, USP, 0.5%